Intellia Therapeutics
NTLA on Nasdaq. Intellia Therapeutics makes gene editing medicines for patients with severe diseases. Market value $1.4bn.
Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-25.51 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 32 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$10.00 a share, 26% above its 1-year low
Over the past year the price has ranged from $7.95 to $18.48.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $33m | $52m | $36m | $58m | $68m |
| Operating margin | |||||
| Operating margin | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.08bn | 0.09bn | 0.10bn | 0.12bn | 0.14bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsSlow, 3.1% a year
- Buying back its own sharesNo, 78% more shares since 2021
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $7 million last quarter, down 48% on a year ago.
- A loss of $127 million, compared with a loss of $101 million a year ago.
- It loses 821 cents on each $1 of sales, compared with 832 cents a year earlier.
- Over the past 12 months it spent $358 million more cash than it brought in, compared with $413 million a year earlier.
- 27% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 1 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $13m |
| March 2025 | $17m |
| June 2025 | $14m |
| September 2025 | $14m |
| December 2025 | $23m |
| March 2026 | $15m |
| June 2026 | $8m |
| September 2026 | $7m |
| Quarter to | Amount |
|---|---|
| December 2024 | -$129m |
| March 2025 | -$114m |
| June 2025 | -$101m |
| September 2025 | -$101m |
| December 2025 | -$96m |
| March 2026 | -$96m |
| June 2026 | -$107m |
| September 2026 | -$127m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 26 February 2026
- Next quarterly (estimated, 10-Q)
- 4 February 2027
Who owns it
1 long-term investor we follow owns it, unchanged from 1 last quarter. 328 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Horizon KineticsMurray Stahl | $212,921 | <0.1% | Cut |
Largest holders overall
- ARK Investment Management$286mAdded
- BlackRock$261mAdded
- State Street$156mAdded
- Vanguard Portfolio Management$124mAdded
- D. E. Shaw$109mAdded
- Vanguard Capital Management$102mAdded
- TWO Sigma Investments, LP$89mAdded
- FMR$81mAdded
- RA Capital Management, L.P.$77mNew
- Regeneron Pharmaceuticals$63m
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
6 investors own more than 5%.
- ARK Investment Management LLCPassive investorat least 12.3%+1.2 pts(filed with 1 related holder)Since 31 December 2025
- BlackRock, Inc.Passive investor8.2%Since 31 March 2025
- STATE STREET CORPORATIONPassive investor5.6%−1.2 ptsSince 30 September 2026
- Vanguard Portfolio ManagementPassive investor5.3%Since 31 March 2026
- Vanguard Capital ManagementPassive investor5.0%Since 31 March 2026
- THE GOLDMAN SACHS GROUP, INC.Passive investorat least 2.7%−2.4 pts(filed with 1 related holder)Since 31 December 2025
- Contrarius Investment Management LtdPassive investorSold down below 5%Since 31 December 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
ARK Investment Management LLC Passive investor | at least 12.3%+1.2 pts (filed with 1 related holder) | 31 December 2025 | |
BlackRock, Inc. Passive investor | 8.2% | 31 March 2025 | |
STATE STREET CORPORATION Passive investor | 5.6%−1.2 pts | 30 September 2026 | |
Vanguard Portfolio Management Passive investor | 5.3% | 31 March 2026 | |
Vanguard Capital Management Passive investor | 5.0% | 31 March 2026 | |
THE GOLDMAN SACHS GROUP, INC. Passive investor | at least 2.7%−2.4 pts (filed with 1 related holder) | 31 December 2025 | |
Contrarius Investment Management Ltd Passive investor | Sold down below 5% | 31 December 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $1m of shares on the open market. 7 sold $2m, $1m of it under preset trading plans.
- LEONARD JOHN MPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 2 November 2026
- Shares
- 9,000
- Price
- $11.99
- Value
- $107,910
- Dube Michael PVP, Chief Accounting OfficerSold
- Date
- 2 October 2026
- Shares
- 1,864
- Price
- $12.43
- Value
- $23,170
- LEONARD JOHN MPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 21 August 2026
- Shares
- 2,785
- Price
- $13.00
- Value
- $36,205
- LEONARD JOHN MPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 20 August 2026
- Shares
- 19,890
- Price
- $12.60
- Value
- $250,614
- Dulac Edward J IIIEVP, Chief Financial OfficerSold
- Date
- 22 July 2026
- Shares
- 8,111
- Price
- $11.25
- Value
- $91,249
- Dulac Edward J IIIEVP, Chief Financial OfficerSoldunder a preset trading plan
- Date
- 2 July 2026
- Shares
- 4,677
- Price
- $18.00
- Value
- $84,186
- Dube Michael PVP, Chief Accounting OfficerSold
- Date
- 1 July 2026
- Shares
- 2,641
- Price
- $16.78
- Value
- $44,316
- BASTA JAMESEVP, General CounselSold
- Date
- 2 March 2026
- Shares
- 1,211
- Price
- $13.78
- Value
- $16,688
- Clark ElianaEVP, Chief Technical OfficerSold
- Date
- 2 March 2026
- Shares
- 607
- Price
- $13.78
- Value
- $8,364
- LEONARD JOHN MPresident and CEO, DirectorSold
- Date
- 5 January 2026
- Shares
- 34,146
- Price
- $9.21
- Value
- $314,485
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 2 November 2026 | LEONARD JOHN M President and CEO, Director | Sold under a preset trading plan | 9,000 | $11.99 | $107,910 |
| 2 October 2026 | Dube Michael P VP, Chief Accounting Officer | Sold | 1,864 | $12.43 | $23,170 |
| 21 August 2026 | LEONARD JOHN M President and CEO, Director | Sold under a preset trading plan | 2,785 | $13.00 | $36,205 |
| 20 August 2026 | LEONARD JOHN M President and CEO, Director | Sold under a preset trading plan | 19,890 | $12.60 | $250,614 |
| 22 July 2026 | Dulac Edward J III EVP, Chief Financial Officer | Sold | 8,111 | $11.25 | $91,249 |
| 2 July 2026 | Dulac Edward J III EVP, Chief Financial Officer | Sold under a preset trading plan | 4,677 | $18.00 | $84,186 |
| 1 July 2026 | Dube Michael P VP, Chief Accounting Officer | Sold | 2,641 | $16.78 | $44,316 |
| 2 March 2026 | BASTA JAMES EVP, General Counsel | Sold | 1,211 | $13.78 | $16,688 |
| 2 March 2026 | Clark Eliana EVP, Chief Technical Officer | Sold | 607 | $13.78 | $8,364 |
| 5 January 2026 | LEONARD JOHN M President and CEO, Director | Sold | 34,146 | $9.21 | $314,485 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Feb 2026, plus the 10-Q filed 5 Nov 2026 and 12 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.